Ikonisys to Start Collaboration with SYNLAB Italy to Introduce Ikoniscope in Pathology Laboratories
04 Novembre 2024 - 6:00PM
Business Wire
Regulatory News:
Ikonisys (Euronext Growth Paris: ALIKO), a company
specializing in the early and accurate detection of cancers through
a unique, fully automated solution for medical analysis
laboratories, today announces the start of a collaboration with
SYNLAB Italy, part of SYNLAB Group, a leader in medical diagnostic
services and specialty testing in Europe, for the implementation of
Ikoniscope, the advanced platform based on Fluorescence In Situ
Hybridization (FISH), in Italy. This initiative marks a significant
step in enhancing oncological diagnosis accuracy and optimizing
personalized treatments for patients.
Ikoniscope by Ikonisys is renowned for its ability to accurately
analyze tumor cells through advanced automated imaging techniques
based on FISH. This approach enables precise identification of
specific genetic alterations, crucial for early diagnosis and
personalized oncological treatments. Ikoniscope thus represents a
cornerstone in SYNLAB's strategy to improve diagnostic accuracy and
optimize therapies for patients.
"We are proud to collaborate with SYNLAB Italy and bring our
advanced diagnostic solutions at the forefront of healthcare
innovation. Together, we aim to set new standards of excellence in
diagnostic precision, enhancing patient care and outcomes. Our
shared vision is to empower healthcare providers with the tools and
insights needed to make informed decisions, ultimately improving
the lives of patients in Italy and beyond. This collaboration
reflects SYNLAB's commitment to offering cutting-edge diagnostic
solutions", says Francesco Trisolini, COO at Ikonisys
Group.
Positive Impact for the Industry
With its ability to process high volumes of analyses
efficiently, Ikoniscope provides critical added value for SYNLAB in
ensuring high-quality service to an expanding number of patients.
SYNLAB's adoption of Ikoniscope not only meets the growing demand
for diagnostic precision but also addresses the increasing need for
innovative solutions in the oncology sector.
New Perspectives in Pap Tests
Thanks to Ikonisys technology integrated into SYNLAB's
diagnostic framework, the introduction of Ikoniscope marks a
transformative leap in the accuracy and precision of Pap test
diagnostics. Specifically tailored for identify ASCUS (Atypical
Squamous Cell of Unknowned Significance) and LSIL (Low-grade
Squamous Intraepithelial Lesions) cells, this advanced system not
only enhances the detection of subtle cellular abnormalities but
also provides detailed insights into their genetic characteristics.
This capability is pivotal in predicting the potential progression
of low-grade neoplasia, thereby facilitating earlier intervention
and more effective treatment strategies.
Through this collaboration, Ikonisys continues its commitment to
pushing the boundaries of diagnostic technology, ensuring that
healthcare providers have access to the most advanced tools
available to better serve their patients. Together with SYNLAB,
Ikonisys looks forward to advancing the field of oncological
diagnosis.
About SYNLAB
SYNLAB Italy is part of SYNLAB Group, the largest European
provider of clinical laboratory and medical diagnostic, as well as
specialty testing services, by revenue and number of tests. SYNLAB
offers a full range of innovative and reliable medical diagnostic
and testing services for patients, practicing doctors, clinics and
the pharmaceutical industry.
More information can be found on www.synlab.it
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to
www.ikonisys-finance.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241104914865/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024